Spinal muscular atrophy is caused by mutation of the SMN1 gene resulting in the selective loss of spinal cord motor neurons. HuD has been shown to interact with SMN and to localize to RNA granules along axons. In conditions where SMN is decreased, like in SMA, HuD’s localization to RNA granules affected. Overexpression of HuD in an SMA cell culture model was shown to rescue SMA-like axonal defects. Here, existence of a signaling pathway downstream of PKC leading to the activation of HuD was investigated in MN-1 cells. Stimulation of this pathway using a pharmacological agonist of PKC increased HuD levels and enhanced its binding to GAP-43 and Tau mRNAs. An scAAV9 viral expression system to overexpress HuD in vivo was established, laying the foundation for the next phase of the study. Overall, modulating HuD expression and activity would be beneficial and could constitute an attractive therapeutic approach for SMA.

京都大学 / 0048 / 新制・課程博士 / 博士(農学) / 甲第19028号 / 農博第2106号 / 新制||農||1030(附属図書館) / 学位論文||H27||N4910(農学部図書室) / 31979 / 京都大学大学院農学研究科食品生物科学専攻 / (主査)教授 入江 一浩, 教授 安達 修二, 教授 保川 清 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DGAM

Under the conditions of transfer hydrogenation employing ortho-cyclometallated iridium C,O-benzoate catalysts, two protocols of iterative chain elongation of 1,3-diols to furnish 1,3-polyols were developed. First, one-directional chain elongation employing mono-protected 1,3-diols as starting materials was achieved. In all cases, high levels of catalyst-directed enantioselectivity and diastereoselectivity were observed. Then, double asymmetric allylation of 1,n-glycols to deliver C₂-symmetric adducts with exceptional level of enantioselectivity was devised. Iterative two-directional elongation of 1,3-diols to furnish 1,3-polyols with high level of catalyst-directed diastereoselectivity was then achieved. Implementation of this methodology and other hydrogenative C-C bond formations proved to be effective means for the preparation of a known bryostatin A-ring fragment and the total synthesis of bryostatin 7. / text

This thesis describes approaches towards the synthesis of 20-deoxybryostatins and 20,20-difluorobryostatins. Towards the 20-deoxybryostatins, a route previously developed within the group was followed with a protecting group change designed to prevent problems encountered with a late-stage deprotection. To this end, (R)-pantolactone was transformed through to dimethyl (4S,6R,8R)-[4-(para-methoxybenzyloxy)-10-hydroxy-6,8-O-isopropylidine-3,3-dimethyl-2-one] phosphonate which was subsequently subjected to a Horner-Wadworth-Emmons condensation with (5R,E)-6-(4-methoxybenzyloxy)-5-triethylsilyloxy-3-(2’-triisopropylsilyloxyethylidene)hexanal. The reactions of the resulting enone through to the advanced intermediate allyl [(4R,6R)-6-((S)-2’-(4-methoxybenzyl)oxy-5-{(2’’S,6’’R)-6’’-(4-methoxybenzyloxymethyl)-4’’-[2-triisopropylsilyloxyeth-(Z)-ylidene]-tetrahydropyran-2’’-yl}-3,3-dimethyl-4’-oxopentyl)-2,2-dimethyl-1,3-dioxan-4-yl]-acetate are described, and this compound corresponds to a C1-C16 northern bryostatin fragment. A synthetic route to 20,20-difluorobryostatins was begun by the synthesis of three 3,3-difluoro-2-hydroxytetrahydro-4H-pyrans which started from an indium-mediated coupling of 3-bromo-3,3-difluoro-1-propene with an aldehyde. A strategy was employed which culminated in the preparation of 3,3-difluoro-2-hydroxy-2-(3-methylbut-1-en-3-yl)-4-(E)-methoxycarbonylmethylenetetrahydro-4H-pyran which corresponds to a C16-C23 20,20-difluorobryostatin southern fragment. Of particular interest is the selectivity observed in the reaction of α,α-difluoroketones with a stabilised Wittig reagent. The indium-mediated coupling was extended to include the first example of the coupling of a 2-alkyl substituted bromide.

Au cours de ces années de Doctorat, nous avons étudié les effets ototoxiques de certains médicaments et les moyens de prévenir les surdités neuro-sensorielles quils peuvent induire. Parmi ces molécules, nous nous sommes concentrés sur les plus couramment utilisées en pratique clinique : les antibiotiques de la famille des aminoglycosides et le cisplatine, un agent anti-cancéreux. Lintroduction de notre travail replace la surdité dans son contexte de santé publique. En particulier, nous décrivons pourquoi les médicaments ototoxiques sont utilisés et dans quelles circonstances. Nous présentons la structure de loreille interne et nous tentons dexpliquer sa vulnérabilité aux molécules ototoxiques. Nous abordons ensuite les moyens de prévention et/ou de traitement de ces atteintes neuro-sensorielles pharmaco-induites. Outre les moyens classiques de prévention, que sont les facteurs trophiques et les antioxydants, nous décrivons de nouvelles voies dapproche que sont les voies de signalisation impliquant la protéine kinase C ou la cascade dactivation RhoA/ROCK. La présentation de notre travail original sarticule autour de deux parties. Dans la première partie, nous rapportons les résultats obtenus au cours de notre étude de la toxicité des aminoglycosides et du cisplatine chez la souris et le cobaye in vivo. Nous avons mis en évidence une différence de vulnérabilité significative entre ces deux espèces face à lagression ototoxique. Cette différence existe au niveau fonctionnel, mis en évidence par létude des potentiels évoqués auditifs, et au niveau anatomique, étudié en histologie et en immunohistochimie. Nous en discutons les implications en recherche et en pratique clinique. Dans la seconde partie, nous étudions les moyens de prévenir cette surdité in vivo et in vitro. Nous avons utilisé un modèle de surdité par aminoglycoside chez le cobaye. Nous avons testé et validé une technique de perfusion intra-cochléaire in vivo. Nous avons observé les effets de deux molécules expérimentales : la Bryostatine 1, un activateur de la protéine kinase C, et un inhibiteur de la voir RhoA-ROCK. Leffet protecteur de ces molécules est actuellement limité au ganglion spiral, dont la survie est essentielle à tout traitement dimplantation prothétique et de réadaptation. Nous discutons des perspectives en médecine humaine dans notre conclusion. In this work, we focused our attention on the effects of main ototoxic drugs i.e. aminoglycosides and cisplatin in mammals. We identified new avenues for the prevention of this toxicity. In the introduction, we described how and why ototoxic drugs are used. We then described potential otoprotective strategies in neurosensory deafness. Among them, trophic factors and antioxidant molecules have been widely used. New otoprotective approaches do exist, implying the protein kinase C or RhoA/ROCK signalling. Our original work was presented in two parts. In the first part, we reported the in vivo effects of aminoglycosides and cisplatin in two mammalian species: mice and guinea pigs. Contrarily to guinea pigs, evidence of mice resistance to ototoxicity was found at a functional level, assessed by auditory brainstem responses, and at an anatomical level, studied by immunohistochemistry. We discussed the implication of such differences in research and in clinical practice. In the second part, we studied the effect of two potential otoprotective molecules: Bryostatine 1, an activator of the protein kinase C, and Y-27632, a Rho kinase inhibitor. We showed that these molecules are protecting spiral ganglion neurons both in vitro and in vivo. Survival of spiral ganglion neurons is crucial in the management and rehabilitation of deafness. The potential perspectives of these results in human medicine were discussed.